NC
ABCL icon

NinePointTwo Capital’s AbCellera Biologics ABCL Stock Holding History

NinePointTwo Capital’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-40,651
Closed -$262K – 248
2023
Q2 		$262K Hold
40,651
– – 0.1% 99
2023
Q1 		$306K Buy
40,651
+25,254
+164% +$229K 0.12% 42
2022
Q4 		$155K Sell
15,397
-18,417
-54% -$213K 0.06% 159
2022
Q3 		$334K Sell
33,814
-20,913
-38% -$229K 0.13% 73
2022
Q2 		$582K Buy
+54,727
New +$463K 0.2% 28

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

NinePointTwo Capital's ABCL Position: Q3 2023 in Review

NinePointTwo Capital sold out of AbCellera Biologics (ABCL) in Q3 2023, closing a stake of 40,651 shares — an estimated $262K sold.

NinePointTwo Capital first reported a position in ABCL in Q2 2022 and held it in 5 quarters. The position peaked at $582K in Q2 2022. 138 funds tracked by Wall St. Rank hold ABCL as of Q3 2023.

  • NinePointTwo Capital reported no remaining AbCellera Biologics position as of Q3 2023 after selling out during the quarter.
  • NinePointTwo Capital sold 40,651 AbCellera Biologics shares in Q3 2023, an estimated $262K.
  • NinePointTwo Capital first reported a position in AbCellera Biologics in Q2 2022 and held it in 5 quarters.
  • NinePointTwo Capital's AbCellera Biologics position peaked at $582K in Q2 2022.
  • 138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2023.

Based on NinePointTwo Capital's 13F filing for Q3 2023, filed 14 Nov 2023.